Navigation Links
Cambrex Reports Second Quarter of 2011 Results
Date:8/2/2011

e impacts and contributed to our strong cash flow in the quarter."

Guidance – Continuing OperationsThe Company continues to expect that sales for 2011, excluding the impact of foreign currency, will increase between 3% and 7% versus 2010, and that full year 2011 EBITDA will be between $43 and $49 million.  EBITDA guidance is for continuing operations and excludes the impact of any M&A or restructuring activities.  The above guidance does not reflect Cambrex Zenara, which is accounted for using the equity method, and as such is not consolidated into the Company's results.  Cambrex's income statement reflects 51% of Cambrex Zenara's net results as Equity in Losses of Partially-Owned Affiliate.  For 2011, the Company continues to expect Cambrex Zenara to have revenues in the low to mid single digit millions and a small EBITDA loss.

Capital expenditures are expected to be approximately $14 to $17 million and depreciation is now expected to be $22 to $24 million in 2011, a $1 million increase over prior guidance due to foreign exchange.

The financial information contained in this press release is unaudited, subject to revision and should not be considered final until the Company's second quarter 2011 Form 10-Q is filed with the SEC.

Conference Call and WebcastThe Conference Call to discuss second quarter of 2011 results will begin at 8:30 a.m. Eastern Time on Wednesday, August 3, 2011 and last approximately 45 minutes.  Those wishing to participate should call 1-888-471-3840 for domestic and +1-719-457-2647 for international.  Please use the pass code 1438939 and call approximately 10 minutes prior to start time.  A webcast is available from the Investors section on the Cambrex website located at www.cambrex.com and can be accessed for 30 days following the conference call.  A telephone replay of the conference call will be available th
'/>"/>

SOURCE Cambrex Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Cambrex Reports Third Quarter 2010 Results
2. Cambrex Reports Fourth Quarter and Full Year 2009 Results
3. Cambrex Continuous-Flow Microwave-Assisted Organic Synthesis Technology Nominated for 2009 Innovations Award
4. Cambrex Reports First Quarter 2009 Results
5. Cambrex Receives Notice Regarding NYSE Listing
6. Cambrex Reports Third Quarter 2008 Results
7. Jennerex Reports Positive Mechanistic Proof-of-Concept Clinical Trial Results Using JX-594 to Treat Metastatic Melanoma
8. Gen-Probe Reports Financial Results for the Second Quarter of 2011
9. Neurocrine Biosciences Reports Second Quarter 2011 Results
10. United Therapeutics Corporation Reports Second Quarter 2011 Financial Results
11. Sangamo BioSciences Reports Second Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... SAN DIEGO and HONG KONG ... an innovative rare disease therapeutics enterprise, announced today that ... joined the company as vice president, research. Dr. McKew ... research, including key leadership positions at the National Institutes ... to its acquisition by Wyeth). Dr. McKew will lead aTyr,s ...
(Date:10/20/2014)... /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today ... to $5.8 million and provides a good start to Q4.  The ... America and one in the Middle East ... record levels," said Peter Bruijns , President & CEO. "Total ... Q3 than they have been for any complete year since the ...
(Date:10/20/2014)... Earle Martin , Chief ... that Ellen Teplitzky, an experienced attorney specializing in ... industry, has joined the firm as Director of ... practice. NDA Partners provides legal services, including ... to top law firms and their clients in ...
(Date:10/19/2014)... The Asia-Pacific Bromine Market report defines and ... and forecast of revenue. , Browse through the ... to get an idea of the in-depth analysis ... segmentation in the Asia-Pacific bromine market, and is ... http://www.micromarketmonitor.com/market/asia-pacific-bromine-6741503144.html , Bromine is a volatile ...
Breaking Biology Technology:aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3NDA Partners Appoints Ellen Teplitzky, JD as Director of its Legal Services Practice 2The Asia-Pacific Bromine Market is estimated to grow to $4,080.1 million by 2018 - New Report by MicroMarket Monitor 2The Asia-Pacific Bromine Market is estimated to grow to $4,080.1 million by 2018 - New Report by MicroMarket Monitor 3
... (Amex: IMA ) today announced that it has ... Australian company traded on,the Australian Securities Exchange, under which ... issued shares in Panbio for AUD 0.65 cash,per share. ... of,Panbio at approximately AUD 41 million, or approximately USD ...
... ExL Pharma, Cision and the PRSA have,joined ... biotech,public relations executives the first Pharmaceutical Public Relations,Symposium ... This,one-day event will cover the key issues and ... is under ongoing political and media scrutiny,most notably ...
... USC,s Increased Commitment to Research Advancements in Health ... Robust Life Science Industry in Los Angeles, LOS ... University of Southern California,s strengthened,commitment to advancing breakthrough research ... today the opening of an office,in the new Harlyne ...
Cached Biology Technology:Inverness Medical Innovations Agrees to Acquire Panbio Ltd. 2Leading Pharmaceutical Communication Executives Gather for the 1st Annual Pharmaceutical Public Relations Symposium 2The USC Stevens Institute for Innovation Opens Shop on US Health Sciences Campus 2The USC Stevens Institute for Innovation Opens Shop on US Health Sciences Campus 3The USC Stevens Institute for Innovation Opens Shop on US Health Sciences Campus 4
(Date:10/17/2014)... regarding Ebola is critical and pertinent for practicing physicians ... outbreak and epidemic. The Journal, Disaster Medicine and ... Ebola Virus and Public Health, to surround the public, ... critical societal moment. , On October 17, the ... . The primer was prepared by Dr. Eric Toner, ...
(Date:10/17/2014)... the University of Copenhagen have shown for the first ... of Cystic fibrosis patients, giving them the opportunity to ... chronic infections. , The study also discovered the bacterial ... patients was halted or slowed down by the immune ... the oxygen and helped "suffocate" the bacteria, forcing the ...
(Date:10/16/2014)... human body. Battles are won, lost or sometimes ... stalemate—known as tumor dormancy—can last up to 25 ... is poorly understood. , A new computational ... a Professor of Chemistry at Princeton University, may ... the switch to a malignant state. Published today ...
Breaking Biology News(10 mins):Scientists opens black box on bacterial growth in cystic fibrosis lung infection 2Modeling tumor dormancy 2
... WHITE PLAINS, N.Y. MAY 28, 2009 -- Starting pregnancy at ... is critical to giving a baby a healthy start in ... new guidelines from the Institute of Medicine (IOM). ... of weight a woman should gain during pregnancy. While the ...
... and Energy Secretary Steve Chu are consistent in their ... biofuels as an alternative to gasoline are coming. While ... has been on global warming, such a shift could ... Biosciences Institute (EBI) has produced a novel and comprehensive ...
... State University engineers have created a non-toxic "wrinkled" coating ... troublesome barnacles during 18 months of seawater tests, a ... dollars in cleaning and fuel costs. The research ... the Department of Chemical and Biomolecular Engineering, and Dr. ...
Cached Biology News:New guidelines to fight obesity in pregnancy issued 2The coming of biofuels: Study shows reducing gasoline emissions will benefit human health 2The coming of biofuels: Study shows reducing gasoline emissions will benefit human health 3The coming of biofuels: Study shows reducing gasoline emissions will benefit human health 4Non-toxic hull coating resists barnacles, may save ship owners millions 2
... Transformation Kit is designed for rapid ... Advantages over commonly used transformation procedures ... methods include:- Cells can be made competent ... cell preparation and transformation solutions are ...
Endomorphin-2. Cross reactivity: Endomorphin-1 3%, Met-enkephalin <0.03%, Leu-enkephalin <0.01% and beta-Endorphin <0.01%....
...
... Error-free cloning of BAC (100+kb), fosmid (40kb), ... insert stability than any othe BAC vector. ... high yields and easy recombinant DNA purification. ... transcription-free (pSMART VC) vectors for the highest ...
Biology Products: